About: Management of early breast cancer during the COVID-19 pandemic in Brazil

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of early breast cancer during the COVID-19 pandemic in Brazil Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Management of early breast cancer during the COVID-19 pandemic in Brazil
Creator	Luiza, Ana Sousa, Lima Camargo Millen, · Felipe, · Guilherme, · Junior, Freitas Novita, Garcia Pimentel Cavalcante, Francisco Ruffo, · Vilmar Marques De Oliveira, · Zerwes, Pereira
Source	Medline; PMC
abstract	PURPOSE: The COVID-19 pandemic has impacted early breast cancer (EBC) treatment worldwide. This study analyzed how Brazilian breast specialists are managing EBC. METHODS: An electronic survey was conducted with members of the Brazilian Society of Breast Cancer Specialists (SBM) between April 30 and May 11, 2020. Bivariate analysis was used to describe changes in how specialists managed EBC at the beginning and during the pandemic, according to breast cancer subtype and oncoplastic surgery. RESULTS: The response rate was 34.4% (503/1462 specialists). Most of the respondents (324; 64.4%) lived in a state capital city, were board-certified as breast specialists (395; 78.5%) and either worked in an academic institute or one associated with breast cancer treatment (390; 77.5%). The best response rate was from the southeast of the country (240; 47.7%) followed by the northeast (128; 25.4%). At the beginning of the pandemic, 43% changed their management approach. As the outbreak progressed, this proportion increased to 69.8% (p < 0.001). The southeast of the country (p = 0.005) and the state capital cities (p < 0.001) were associated with changes at the beginning of the pandemic, while being female (p = 0.001) was associated with changes during the pandemic. For hormone receptor-positive tumors with the best prognosis (Ki-67 < 20%), 47.9% and 17.7% of specialists would recommend neoadjuvant endocrine therapy for postmenopausal and premenopausal women, respectively. For tumors with poorer prognosis (Ki-67 > 30%), 34% and 10.9% would recommend it for postmenopausal and premenopausal women, respectively. Menopausal status significantly affected whether the specialists changed their approach (p < 0.00001). For tumors ≥ 1.0 cm, 42.9% of respondents would recommend neoadjuvant systemic therapy for triple-negative tumors and 39.6% for HER2 + tumors. Overall, 63.4% would recommend immediate total breast reconstruction, while only 3.4% would recommend autologous reconstruction. In breast-conserving surgery, 75% would recommend partial breast reconstruction; however, 54.1% would contraindicate mammoplasty. Furthermore, 84.9% of respondents would not recommend prophylactic mastectomy in cases of BRCA mutation. CONCLUSIONS: Important changes occurred in EBC treatment, particularly for hormone receptor-positive tumors, as the outbreak progressed in each region. Systematic monitoring could assure appropriate breast cancer treatment, mitigating the impact of the pandemic.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1007/s10549-020-05877-y
bibo:pmid	32803637
has license	no-cc
sha1sum (hex)	b48d8941290f7deb26dfc85611e0bfe60813d0ff
schema:url	https://doi.org/10.1007/s10549-020-05877-y
resource representing a document's title	Management of early breast cancer during the COVID-19 pandemic in Brazil
has PubMed Central identifier	PMC7429139
has PubMed identifier	32803637
schema:publication	Breast Cancer Res Treat
resource representing a document's body	covid:b48d8941290f7deb26dfc85611e0bfe60813d0ff#body_text
is schema:about of	named entity 'describe' named entity 'postmenopausal' named entity 'Specialists' named entity 'changed' named entity 'surgery' named entity 'premenopausal' named entity 'breast cancer' named entity 'HOW' named entity '30%' named entity 'THEIR' named entity 'REGION' named entity 'NORTHEAST' named entity 'ASSOCIATED WITH' named entity 'PREMENOPAUSAL WOMEN' named entity 'POSTMENOPAUSAL' named entity 'mitigating' named entity 'subtype' named entity 'partial' named entity 'electronic' named entity 'response rate' named entity 'systemic therapy' named entity 'Ki-67' named entity 'changed' named entity 'For' named entity 'premenopausal' named entity 'outbreak' named entity 'managing' named entity 'breast reconstruction' named entity 'BRCA mutation' named entity 'autologous' named entity 'premenopausal' named entity 'oncoplastic surgery' named entity 'prophylactic mastectomy' named entity 'tumors' named entity 'tumors' named entity 'Menopausal' named entity 'systemic therapy' named entity 'neoadjuvant' named entity 'breast cancer' named entity 'Most' named entity 'Autologous' named entity 'significant effect' named entity 'COVID' named entity 'proliferation index' named entity 'May 11' named entity 'stage II' named entity 'Breast Cancer' named entity 'HR-positive' named entity 'HR-positive' named entity 'Spain' named entity 'demographic characteristics' named entity 'breast cancer' named entity 'HER2' named entity 'BRCA' named entity 'COVID-19 pandemic' named entity 'statistical analysis' named entity 'tissue expanders' named entity 'T1/2' named entity 'Ki-67' named entity 'luminal' named entity 'adjuvant therapy' named entity '95% CI' named entity 'HER2' named entity 'axillae' named entity 'HER2' named entity 'menopausal' named entity 'Brazil' named entity 'breast cancer' named entity 'luminal' named entity 'proliferation index' named entity 'de-escalating'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software